Cost-Saving MeasuresOPKO has identified additional cost-saving measures, targeting $10 million in annualized cost reductions.
Partnership And AcquisitionsOPKO entered an agreement with Labcorp for Labcorp to acquire laboratory testing businesses focused on oncology and oncology-related clinical testing services across the U.S. from BioReference Health, a wholly owned subsidiary of OPKO.
Stock Repurchase ProgramOPKO Health announced that its board of directors had authorized an increase of $100M in the company’s existing common stock repurchase program, bringing the aggregate capacity of the program to $200M.